BIIB

Biogen
D

BIIB

Arincen57/100B

Biogen income statement 1985–2026

10.30B USD over the last twelve months, and 9.89B USD in fiscal year 2025.

Revenue Operating income Net income

Click a line's chart icon in the table to add it to the chart; hover over it for a quick look.

Fiscal year
TTM
30 Sept 2026
FY2025
31 Dec 2025
FY2024
31 Dec 2024
FY2023
31 Dec 2023
FY2022
31 Dec 2022
FY2021
31 Dec 2021
FY2020
31 Dec 2020
FY2019
31 Dec 2019
FY2018
31 Dec 2018
FY2017
31 Dec 2017
FY2016
31 Dec 2016
Revenue
10.30B9.89B9.68B9.84B10.17B10.98B13.44B14.38B13.45B12.27B11.45B
Revenue growth
+2.30%+2.22%-1.62%-3.32%-7.36%-18.32%-6.49%+6.88%+9.61%+7.21%+6.36%
Cost of revenue
3.08B2.90B2.31B2.53B2.28B2.11B1.81B1.96B1.82B1.63B1.43B
Gross profit
7.21B6.91B7.37B7.30B7.90B8.87B11.64B12.42B11.64B10.64B10.02B
Gross margin
70.05%69.90%76.12%74.24%77.61%80.79%86.57%86.40%86.50%86.72%87.48%
Research and development
2.15B1.95B2.49B2.70B2.60B3.40B4.53B2.77B2.71B2.37B1.97B
Selling, general and administrative
2.75B2.43B2.39B2.50B2.41B2.68B2.52B2.36B2.11B1.94B1.95B
Operating expenses
6.43B5.04B4.88B5.20B5.01B6.08B7.05B5.38B5.75B5.30B4.86B
786.90M1.88B2.49B2.10B2.89B2.79B4.59B7.04B5.89B5.35B5.15B
Operating income growth
-67.80%-24.61%+18.74%-27.41%+3.50%-39.22%-34.78%+19.60%+10.15%+3.77%+5.33%
Operating margin
7.64%18.98%25.74%21.32%28.40%25.42%34.16%48.98%43.77%43.55%45.00%
Interest income
109.70M87.80M67.60M276.50M89.30M11.00M42.00M120.00M112.50M78.50M63.40M
Interest expense
304.90M246.00M250.30M246.90M246.60M253.60M222.50M187.40M200.60M250.80M260.00M
Other non-operating income
-496.80M-476.00M-584.30M-800.50M705.30M-1.01B459.80M3.90M11.00M-217.00M-218.70M
Pretax income
290.10M1.40B1.91B1.30B3.59B1.78B5.05B7.05B5.90B5.13B4.93B
Income tax
-57.89M108.11M273.80M135.30M632.80M52.50M992.30M1.16B1.43B2.46B1.24B
Effective tax rate
-19.95%7.71%14.37%10.43%17.61%2.95%19.64%16.43%24.16%47.94%25.08%
347.50M1.29B1.63B1.16B3.05B1.56B4.00B5.89B4.43B2.54B3.70B
Net income growth
-78.40%-20.76%+40.57%-61.89%+95.80%-61.10%-32.06%+32.90%+74.50%-31.43%+4.39%
Net margin
3.37%13.08%16.87%11.81%29.95%14.17%29.76%40.96%32.93%20.69%32.34%
Basic shares
147.35M146.70M145.70M144.70M145.30M149.10M160.90M187.10M204.90M212.60M218.40M
Diluted shares
147.90M146.70M145.90M145.60M146.00M149.60M161.30M187.40M205.30M213.00M218.80M
Change in diluted shares
+1.13%+0.55%+0.21%-0.27%-2.41%-7.25%-13.93%-8.72%-3.62%-2.65%-5.36%
EPS (basic)
2.368.8511.208.0220.9710.4424.8631.4721.6211.9416.96
EPS (diluted)
2.348.8311.197.9720.8710.4024.8031.4221.5811.9216.93
EPS growth
-78.71%-21.09%+40.40%-61.81%+100.67%-58.06%-21.07%+45.60%+81.04%-29.59%+10.37%
EBITDA
1.45B2.95B3.00B2.38B3.54B3.92B5.11B7.74B7.01B6.61B6.39B
EBITDA margin
14.07%29.78%30.96%24.17%34.77%35.73%38.00%53.83%52.14%53.84%55.83%
EBIT
566.80M2.17B2.32B1.88B3.02B3.44B4.65B7.28B6.36B5.89B5.71B

Figures in USD. Shares and EPS are adjusted for stock splits. Quarterly growth is on the same quarter a year before; TTM is the last four quarters.

Figures underlined with dots are from the company's SEC filings, where our data provider's differ.

Common questions about Biogen's income statement

Source: Financial Modeling Prep